AN2 Therapeutics Director Margaret M. FitzPatrick Acquires 2,098 Shares of Common Stock

On September 1, 2026, Margaret M. FitzPatrick, a director of AN2 Therapeutics, Inc. (NASDAQ: ANTX), reported the open-market purchase of 2,098 shares of the company's common stock at a price of $5.53 per share. The transaction was executed on September 1, 2026, and reported on Form 4 on September 2, 2026, with the purchase coded as an acquisition of direct ownership. Following this transaction, FitzPatrick beneficially owns 10,708 shares of AN2 Therapeutics common stock directly. The filing was signed by Lucy Day as attorney-in-fact on behalf of FitzPatrick. This insider purchase reflects an increase in the director's direct stake in the company and was reported in accordance with Section 16 filing requirements. No derivative securities were reported in connection with this filing, and no other ownership changes were disclosed. The transaction is a routine ownership report by a director and does not indicate any change in corporate control or executive leadership.